ProCE Banner Activity

Evolution of Acute and Preventive Treatment of Migraine

Clinical Thought
My reflection on how far we’ve come in improving the treatment of acute and chronic migraine, from triptans and beta-blockers to small molecules and monoclonal antibodies that target CGRP.

Released: March 26, 2020

Expiration: March 25, 2021

No longer available for credit.

Share

Faculty

Robert G. Kaniecki

Robert G. Kaniecki, MD

Director, UPMC Headache Center
Chief, Headache Division
Director, Headache Fellowship Training Program
Assistant Director, Neurology Residency Training Program
Associate Professor of Neurology
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Allergan

Amgen, Inc.

Lundbeck

Faculty Disclosure

Primary Author

Robert G. Kaniecki, MD

Director, UPMC Headache Center
Chief, Headache Division
Director, Headache Fellowship Training Program
Assistant Director, Neurology Residency Training Program
Associate Professor of Neurology
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Robert G. Kaniecki, MD, has no relevant conflicts of interest to disclose.